Rapport Therapeutics Chief Development Officer Krishnaswamy Yeleswaram disposes of common shares worth $2.51 million
RAPP•Insider share sales
Rapport Therapeutics Chief Development Officer Yeleswaram Krishnaswamy sold 50,160 common shares on Aug. 24-25.
- The sales were priced at about $50 to $51 per share.
- After the transactions, his holdings totaled 195,862 common shares.
